Pharmaceutical and financial stocks see varied market activity

Several pharmaceutical and financial companies saw significant stock movement and insider activity.

Hengrui Medicine shares rose over 5% following a report from Citigroup. The bank raised its target price for the company, citing a deal to sell exclusive rights for two drugs to Novo Nordisk. The potential value of this transaction is estimated at $2.6 billion, which is expected to drive revenue and profit growth through 2027 and 2028.

Xeris Biopharma Holdings, Inc. shares increased by 5.2% during mid-day trading. This follows several analyst updates, including a price target increase from Barclays and an upgrade from Wall Street Zen. Separately, insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma on September 28th under a pre-arranged Rule 10b5-1 trading plan.

Ultragenyx Pharmaceutical Inc. saw its stock rise 5.8% on Tuesday. While various analysts have recently adjusted their price targets and ratings for the company, it maintains a market capitalization of $1.51 billion.

StoneX Group Inc. CEO Philip Smith sold 56,250 shares of stock on September 28th at an average price of $65.69, totaling approximately $3.69 million. The sale was conducted via a pre-arranged Rule 10b5-1 trading plan.